Vischer advised Anokion in this transaction, while Walder Wyss advised Pfizer. Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune...
You must be a Standard 1 Year member to access this content.
Vischer advised Norgine Ventures on the deal. Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies.The financing was realised in form of...
You must be a Standard 1 Year member to access this content.
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Versantis with Mark Fitzpatrick as CEO, Vincent Forster as CSO and Meriam Kabbaj as COO. Goodwin advised the sellers. Linklaters and Niederer Kraft...
You must be a Standard 1 Year member to access this content.
VISCHER and Dechert advised Forty51 Ventures on the deal. FORTY51 Ventures, a Biotech venture capital firm, closed its first fund, FORTY51 Ventures Fund I SCSp, FIAR,...
You must be a Standard 1 Year member to access this content.
VISCHER advised Mosanna Therapeutics AG on the deal. Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for...
You must be a Standard 1 Year member to access this content.
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
You must be a Standard 1 Year member to access this content.
Vischer advised Redbiotec on the deal. Eurocine Vaccines and Redbiotec have signed a research and partnership agreement for the development of vaccine candidates against Herpes Simplex...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Engimmune Therapeutics on the deal. Vischer advised the investors Pureos Bio-ventures and Novo Holdings. Engimmune Therapeutics completed a CHF 15.5m seed financing round co-led...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. VISCHER advised Cimeo Therapeutics. Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel...
You must be a Standard 1 Year member to access this content.
Walder Wyss acted as Swiss legal counsel for Alloy Therapeutics Inc on the deal. Vischer advised deepCDR Biologics AG. Alloy Therapeutics, a biotechnology ecosystem company, acquired...
You must be a Standard 1 Year member to access this content.
Kellerhals Carrard advised Vifor Pharma on the transaction. Vischer advised Inositec on the deal. Vifor Pharma acquired the Swiss firm Inositec AG, a clinical stage biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
